OAT vs. CPAP — What the Clinical Evidence Shows

This article is written for sleep physicians, pulmonologists, and other providers managing patients with obstructive sleep apnea who are considering or discussing oral appliance therapy as an alternative or adjunct to CPAP.

The clinical question of how oral appliance therapy (OAT) compares to CPAP for obstructive sleep apnea has been studied extensively over the past two decades. The evidence base has matured considerably, and the current literature supports a more nuanced conclusion than the traditional hierarchy of “CPAP is gold standard, OAT is for failures.”

This summary reviews the key evidence — with particular attention to the real-world effectiveness data that should inform shared decision-making with patients.

Efficacy: What the Laboratory Data Shows

In controlled settings with verified usage, CPAP reduces AHI more completely than OAT. This is the basis for CPAP’s historical designation as the first-line treatment for OSA.

The efficacy data for OAT in mild-to-moderate OSA (AHI 5–30):

• AHI reduction of 75–85% in mild-to-moderate OSA (Doff et al., 2013; Sutherland et al., 2014)
• Treatment success (AHI < 5) achieved in approximately 50–65% of patients
• Partial response (AHI reduction >50%) in an additional 20–25% of patients
• Oxygen desaturation index improvement comparable to AHI improvement

For severe OSA (AHI >30), OAT efficacy is lower, though still clinically significant for CPAP-intolerant patients. A 2019 meta-analysis found that OAT reduced AHI by a mean of 13.7 events/hour in severe OSA patients — a meaningful reduction even when normalization is not achieved.

The Adherence Problem: Why Efficacy Comparisons Are Incomplete

Laboratory efficacy data answers one question: how well does this treatment work when used correctly? It does not answer the clinically more relevant question: how well does this treatment work for real patients over real time?

The adherence literature tells a starkly different story than the efficacy literature:

• CPAP adherence at one year: 46–60% of patients (Kribbs et al., 1993; Engleman & Wild, 2003)
• Objective CPAP usage in “adherent” patients: average 3.3–4.5 hours per night
• OAT adherence at one year: 76–88% of patients (Sutherland et al., 2014)
• Objective OAT usage in adherent patients: average 6.5–7.0 hours per night

When Montserrat et al. (2001) and Bartolucci et al. (2016) calculated effective AHI reduction accounting for actual nightly usage rather than device-on efficacy, OAT produced effective AHI reductions of 55–68% versus 40–55% for CPAP in real-world populations.

A treatment that is 90% effective when used is less clinically valuable than a treatment that is 80% effective when patients actually use it. This reframing is important for shared decision-making — particularly for patients who have expressed reluctance about CPAP or have a history of non-adherence.

Patient-Centered Outcomes

The patient-reported outcome literature consistently favors OAT over CPAP:

• Patient preference: In crossover studies, 76% of patients prefer OAT versus 19% who prefer CPAP (Engleman et al., 2002)
• Daytime sleepiness: Epworth Sleepiness Scale improvement is comparable between OAT and CPAP (Aarab et al., 2011; Sharples et al., 2014)
• Quality of life: FOSQ (Functional Outcomes of Sleep Questionnaire) improvements are equivalent or favor OAT
• Partner satisfaction: Partners of OAT patients report significantly higher satisfaction with treatment compared to CPAP
• Snoring: OAT produces equivalent or superior snoring reduction compared to CPAP

The 2015 AASM/AADSM joint clinical practice guideline now recommends OAT as a first-line option for patients with mild-to-moderate OSA and as an acceptable alternative to CPAP for patients with OSA of any severity who cannot tolerate CPAP.

Cardiovascular Outcomes: The Emerging Evidence

The cardiovascular outcome literature for OAT has been slower to develop than for CPAP, but the emerging data is encouraging.

A landmark 2019 study (Anandam et al.) found that OAT produced comparable reductions in 24-hour blood pressure to CPAP in OSA patients with hypertension — despite the lower AHI reduction — potentially because the longer duration of use with OAT offsets the lower per-hour efficacy.

A 2021 retrospective cohort study (Vecchierini et al.) found that long-term OAT use was associated with reduced major adverse cardiovascular events, with outcomes comparable to CPAP-treated patients.

The mechanistic explanation may relate to the sympathetic activation profile: CPAP reduces AHI acutely but creates its own arousal burden through mask interface discomfort. OAT may produce a smoother sympathetic profile through the night due to higher comfort and fewer pressure-related arousals — even with less complete AHI normalization.

This evidence is preliminary and should be interpreted cautiously. But it supports the position that for CPAP-intolerant patients, OAT is not merely a consolation treatment — it is a clinically meaningful intervention with cardiovascular benefit potential.

The TMD-OSA Intersection: What Changes When Both Are Present

Approximately 25–35% of OSA patients have concurrent TMJ dysfunction (Duarte et al., 2021). This intersection has clinical implications for both diagnosis and treatment that are frequently overlooked in standard sleep medicine practice.

For diagnosis: Sleep bruxism — reported in 25–50% of OSA patients — is now understood to be largely a physiological response to airway instability rather than a stress habit. The OPPERA cohort found a 73% increased risk of TMD in patients with two or more OSA symptoms. Patients presenting with both morning jaw pain and sleep apnea symptoms should be evaluated for both conditions before a treatment plan is finalized.

For CPAP patients: CPAP has been shown to worsen jaw clenching in some patients through mask interface pressure on the mandible and through residual arousal events that trigger bruxism reflexes. Patients on CPAP who report worsening or new jaw pain should be evaluated for TMD — and the interaction between the CPAP mask interface and jaw position should be considered.

For OAT candidates: Patients with both OSA and TMD require a device designed with awareness of both conditions. A standard mandibular advancement device (MAD) fabricated without attention to condylar position and joint loading can exacerbate TMJ symptoms — particularly in patients with disc displacement or degenerative joint disease. At a specialty TMJ practice, the oral appliance is engineered to simultaneously advance the mandible for airway management and position the condyle in its orthopedic rest position — addressing both conditions with a single device.

This dual-function design is not available from a general dental practice and requires the treating provider to have expertise in both sleep medicine and TMJ. It is one of the primary clinical advantages of referral to a specialist practice for OSA patients with concurrent TMD.

Selecting Patients for OAT: A Clinical Framework

Based on current evidence and clinical experience, the following framework can guide patient selection for OAT referral:

Strong OAT Candidates

• Mild-to-moderate OSA (AHI 5–30) with no severe nocturnal oxygen desaturation
• CPAP intolerance of any severity — mask fit, pressure, claustrophobia, aerophagia
• Concurrent TMD — OAT addresses both conditions; CPAP may worsen jaw symptoms
• Active lifestyle / frequent travel — portability and lack of power requirement
• Strong patient preference for non-CPAP therapy after informed discussion
• Positional OSA — OAT combined with positional therapy can be highly effective

OAT with Caution / Co-management

• Severe OSA (AHI >30) — OAT may not normalize AHI; combination therapy or close monitoring required
• Significant nocturnal hypoxemia — ensure follow-up sleep testing verifies adequacy
• Active periodontal disease or significant tooth loss — appliance retention may be compromised
• Severe pre-existing TMD with DDNR — appliance mandibular advancement requires careful titration to avoid exacerbating joint symptoms

CPAP Preferred

• Severe OSA with significant cardiac or respiratory comorbidity requiring complete AHI normalization
• Central sleep apnea components — OAT does not address central events
• Complex-treatment emergent central apnea — requires PAP therapy titration

Follow-Up Sleep Testing After OAT

Objective verification of OAT efficacy is standard of care and should be coordinated between the dental sleep provider and the referring sleep physician. At Restorative Wellness Center, follow-up sleep testing is coordinated at 8–12 weeks post-titration — after the appliance has been advanced to the optimal therapeutic position.

Home sleep testing is appropriate for most patients. In-lab testing is preferred when:

• Baseline study was in-lab and comparison data is needed
• Significant nocturnal hypoxemia was present at baseline
• Clinical response is ambiguous or incomplete
• Concurrent parasomnias or complex sleep architecture require attended monitoring

Results are communicated directly to the referring sleep physician, and treatment adjustments are made in coordination. We do not manage these patients in isolation.

A Note on Device Quality

Not all oral appliances are equivalent. Over-the-counter and generic “boil-and-bite” devices have no place in the treatment of diagnosed OSA — they lack the precision of fabrication required for effective mandibular advancement and cannot be titrated. The evidence supporting OAT efficacy is based on custom-fabricated, titratable devices made from precision digital or physical impressions by qualified dental laboratories.

At Restorative Wellness Center, all appliances are fabricated from Trios digital scans to laboratory specification. Titration follows a systematic protocol with follow-up appointments at defined intervals. The process is documented and communicated to the referring provider at each stage.

Related: Sleep Apnea Without CPAP | Orthotic Appliance Therapy | When to Refer to a TMJ Specialist